Movement Alert｜Keymed Biosciences Rises 7.1% in Regular Trading, Profit Alert and Sector-Wide Institutional Buying Boost Shares

Market Focus07-20

On July 20, Keymed Biosciences (02162.HK) rose 7.1% in regular trading, trading at HK$87.9/share, with turnover of HK$53.46 million.

On the news front, the innovative drug sector saw broad-based strength as multiple top-tier public fund managers triggered mandatory disclosure thresholds for Hong Kong-listed innovative drug stocks, signaling strong institutional conviction. The rally was further underpinned by the company's recent profit alert, which projected H1 net profit of no less than RMB 1.2 billion, a dramatic turnaround from a loss of approximately RMB 79 million in the prior-year period. Core product Kanyueda recorded H1 revenue exceeding RMB 390 million, representing year-over-year growth of over 132%, with the commercial team now covering more than 1,600 hospitals across 260 cities.

Additionally, Goldman Sachs increased its position by 287,500 shares on July 13 at an average price of HK$81.19, lifting its stake to 5.00%. The confluence of earnings momentum, institutional accumulation, and sector-level fund rotation collectively drove the intraday advance.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1175845079?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-20 10:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175845079","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Keymed Biosciences Rises 7.1% in Regular Trading, Profit Alert and Sector-Wide Institutional Buying Boost Shares","media":"Market Focus","content":"<p><p>On July 20, Keymed Biosciences (02162.HK) rose 7.1% in regular trading, trading at HK$87.9/share, with turnover of HK$53.46 million.</p><p>On the news front, the innovative drug sector saw broad-based strength as multiple top-tier public fund managers triggered mandatory disclosure thresholds for Hong Kong-listed innovative drug stocks, signaling strong institutional conviction. The rally was further underpinned by the company's recent profit alert, which projected H1 net profit of no less than RMB 1.2 billion, a dramatic turnaround from a loss of approximately RMB 79 million in the prior-year period. Core product Kanyueda recorded H1 revenue exceeding RMB 390 million, representing year-over-year growth of over 132%, with the commercial team now covering more than 1,600 hospitals across 260 cities.</p><p>Additionally, Goldman Sachs increased its position by 287,500 shares on July 13 at an average price of HK$81.19, lifting its stake to 5.00%. The confluence of earnings momentum, institutional accumulation, and sector-level fund rotation collectively drove the intraday advance.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Keymed Biosciences Rises 7.1% in Regular Trading, Profit Alert and Sector-Wide Institutional Buying Boost Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Keymed Biosciences Rises 7.1% in Regular Trading, Profit Alert and Sector-Wide Institutional Buying Boost Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-20 10:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 20, Keymed Biosciences (02162.HK) rose 7.1% in regular trading, trading at HK$87.9/share, with turnover of HK$53.46 million.</p><p>On the news front, the innovative drug sector saw broad-based strength as multiple top-tier public fund managers triggered mandatory disclosure thresholds for Hong Kong-listed innovative drug stocks, signaling strong institutional conviction. The rally was further underpinned by the company's recent profit alert, which projected H1 net profit of no less than RMB 1.2 billion, a dramatic turnaround from a loss of approximately RMB 79 million in the prior-year period. Core product Kanyueda recorded H1 revenue exceeding RMB 390 million, representing year-over-year growth of over 132%, with the commercial team now covering more than 1,600 hospitals across 260 cities.</p><p>Additionally, Goldman Sachs increased its position by 287,500 shares on July 13 at an average price of HK$81.19, lifting its stake to 5.00%. The confluence of earnings momentum, institutional accumulation, and sector-level fund rotation collectively drove the intraday advance.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02162","symbol_name":"康诺亚-B","start_time":0,"source_url":"","article_id":"1175845079","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175845079","pubTimestamp":1784514953,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 20, Keymed Biosciences (02162.HK) rose 7.1% in regular trading, trading at HK$87.9/share, with turnover of HK$53.46 million.On the news front, the innovative drug sector saw broad-based...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02162":"康诺亚-B"},"translate_title":"走势警报|Keymed Biosciences 常规交易上涨 7.1%，盈利警报和全行业机构买入提振股价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1},"content_text":"On July 20, Keymed Biosciences (02162.HK) rose 7.1% in regular trading, trading at HK$87.9/share, with turnover of HK$53.46 million.On the news front, the innovative drug sector saw broad-based strength as multiple top-tier public fund managers triggered mandatory disclosure thresholds for Hong Kong-listed innovative drug stocks, signaling strong institutional conviction. The rally was further underpinned by the company's recent profit alert, which projected H1 net profit of no less than RMB 1.2 billion, a dramatic turnaround from a loss of approximately RMB 79 million in the prior-year period. Core product Kanyueda recorded H1 revenue exceeding RMB 390 million, representing year-over-year growth of over 132%, with the commercial team now covering more than 1,600 hospitals across 260 cities.Additionally, Goldman Sachs increased its position by 287,500 shares on July 13 at an average price of HK$81.19, lifting its stake to 5.00%. The confluence of earnings momentum, institutional accumulation, and sector-level fund rotation collectively drove the intraday advance.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1175845079","isCrawlerRequest":true}